Cresco Labs Inc.

Cresco Labs Inc. reported strong financial results for the second quarter ended June 30, 2026, with revenue increasing to $173 million and a significant turnaround to a net income of $15 million from a prior-year loss. The company also achieved an Adjusted EBITDA of $40 million and maintained its No. 1 market share position in several key markets. Additionally, Cresco Labs secured a new $50.0 million Revolving Credit Facility during the quarter.

Cresco Labs reported Q1 2026 revenue of $151.3 million and a net loss of $17.0 million, compared to $165.8 million revenue and a $15.2 million net loss in Q1 2025. The company achieved an Adjusted EBITDA of $33 million with a 21.7% margin. Subsequent to the quarter, the Trump Administration reclassified medical marijuana to Schedule III, a significant development expected to eliminate Section 280E for Cresco's medical operations. The company also expanded its footprint with a conditional Texas license, two new Ohio dispensaries, and a management agreement for nine Pennsylvania dispensaries.